Cargando…

(18)F-FDG PET/CT to predict tumor PD-L1 expression and response to PD-(L)1 blockade in patients with non-small-cell lung cancer

Detalles Bibliográficos
Autores principales:	Borm, Frank Johannes, De Langen, Adrianus Johannes
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399425/ https://www.ncbi.nlm.nih.gov/pubmed/32802470 http://dx.doi.org/10.21037/jtd.2020.03.12

Ejemplares similares

Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodes
por: Borm, Frank J., et al.
Publicado: (2023)

PD-L1 in Lung Adenocarcinoma: Insights into the Role of (18)F-FDG PET/CT
por: Cui, Yan, et al.
Publicado: (2020)

Value of (18)F-FDG-PET to predict PD-L1 expression and outcomes of PD-1 inhibition therapy in human cancers
por: Kaira, Kyoichi, et al.
Publicado: (2021)

Prognostic significance of PD-L1 expression and (18)F-FDG PET/CT in surgical pulmonary squamous cell carcinoma
por: Zhang, Minghui, et al.
Publicado: (2017)

Retrospective analysis of the prognostic value of PD-L1 expression and (18)F-FDG PET/CT metabolic parameters in colorectal cancer
por: Jiang, Hao, et al.
Publicado: (2020)

Retrospective Analysis of the Predictive Value of (18)F-FDG PET/CT Metabolic Parameters for PD-L1 Expression in Cervical Cancer
por: Ji, Jianfeng, et al.
Publicado: (2023)

Predicting PD-L1 expression status in patients with non-small cell lung cancer using [(18)F]FDG PET/CT radiomics
por: Zhao, Xiaoqian, et al.
Publicado: (2023)

A novel [(89)Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer
por: Puyalto, Ander, et al.
Publicado: (2023)

A comparative (18)F-FDG and an anti-PD-L1 probe PET/CT imaging of implant-associated Staphylococcus aureus osteomyelitis
por: Ren, Shu-Qi, et al.
Publicado: (2023)

The efficiency of (18)F-FDG PET-CT for predicting the major pathologic response to the neoadjuvant PD-1 blockade in resectable non-small cell lung cancer
por: Tao, Xiuli, et al.
Publicado: (2020)

Predictive value of (18)F-FDG PET/CT for evaluating the response to hypofractionated radiotherapy combined with PD-1 blockade in non-small cell lung cancer
por: Tang, Shan, et al.
Publicado: (2023)

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade
por: Bai, Jie, et al.
Publicado: (2017)

Evaluation of PD-L1 Expression Level in Patients With Non-Small Cell Lung Cancer by (18)F-FDG PET/CT Radiomics and Clinicopathological Characteristics
por: Li, Jihui, et al.
Publicado: (2021)

(18)F-FDG PET/CT in Relapsed Endometrial Cancer Treated with Preoperative PD-1 Inhibitor Dostarlimab
por: Seban, Romain-David, et al.
Publicado: (2021)

Prospective assessment using (18)F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer
por: Yamaguchi, Ou, et al.
Publicado: (2022)

An update on immunotherapy with PD-1 and PD-L1 blockade
por: Koh, Sung Ae
Publicado: (2021)

Metabolic Tumor Volume Measured by (18)F-FDG PET/CT is Associated with the Survival of Unresectable Hepatocellular Carcinoma Treated with PD-1/PD-L1 Inhibitors Plus Molecular Targeted Agents
por: Wang, Xuezhu, et al.
Publicado: (2023)

Relationship between PD-L1 expression and (18)F-FDG uptake in gastric cancer
por: Chen, Ruohua, et al.
Publicado: (2019)

Quantitative Dynamic (18)F-FDG PET/CT in Survival Prediction of Metastatic Melanoma under PD-1 Inhibitors
por: Sachpekidis, Christos, et al.
Publicado: (2021)

Interim [(18)F]FDG PET/CT can predict response to anti-PD-1 treatment in metastatic melanoma
por: Sachpekidis, Christos, et al.
Publicado: (2020)

Prognostic significance of volume-based (18)F-FDG PET/CT parameters and correlation with PD-L1 expression in patients with surgically resected lung adenocarcinoma
por: Wang, Dalong, et al.
Publicado: (2021)

Human Cancer Immunotherapy with PD-1/PD-L1 Blockade
por: Zheng, Peilin, et al.
Publicado: (2015)

Genetic biomarkers for PD-1/PD-L1 blockade therapy
por: Kataoka, Keisuke, et al.
Publicado: (2016)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade
por: Brancatella, Alessandro, et al.
Publicado: (2021)

PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
por: Bocanegra, Ana, et al.
Publicado: (2020)

From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
por: Zhao, Xuan, et al.
Publicado: (2022)

Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade
por: Freeman, Gordon J., et al.
Publicado: (2006)

Adipose PD-L1 Modulates PD-1/PD-L1 Checkpoint Blockade Immunotherapy Efficacy in Breast Cancer
por: Wu, Bogang, et al.
Publicado: (2018)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
por: Lee, Hyun Tae, et al.
Publicado: (2017)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
por: Wu, Mengling, et al.
Publicado: (2022)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
por: Grecea, Miruna, et al.
Publicado: (2021)

PD-1/PD-L1 blockade in cancer treatment: perspectives and issues
por: Hamanishi, Junzo, et al.
Publicado: (2016)

Oncolytic virus and PD-1/PD-L1 blockade combination therapy
por: Chen, Chun-Yu, et al.
Publicado: (2018)

Drug response to PD-1/PD-L1 blockade: based on biomarkers
por: Chen, Qi, et al.
Publicado: (2018)

Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
por: Zhao, Bin, et al.
Publicado: (2020)

Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas
por: Katsuya, Hiroo, et al.
Publicado: (2023)

PD-1/PD-L1 blockades in non-small-cell lung cancer therapy
por: Jing, Wang, et al.
Publicado: (2016)

Relationship between standardized uptake value on 18F-FDG PET and PD-L1 expression in clear cell renal cell carcinoma
por: Liu, Ying, et al.
Publicado: (2022)

Relationship between SUVmax on 18F-FDG PET and PD-L1 expression in liver metastasis lesions after colon radical operation
por: Qiao, Yan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3c6prq8fbrrk3vcr0s3pgtj6re